Dopamine Agonists and the Risk of Cardiac-Valve Regurgitation
Top Cited Papers
- 4 January 2007
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 356 (1) , 29-38
- https://doi.org/10.1056/nejmoa062222
Abstract
Case reports and echocardiographic studies suggest that the ergot-derived dopamine agonists pergolide and cabergoline, used in the treatment of Parkinson's disease and the restless legs syndrome, may increase the risk of cardiac-valve regurgitation.Keywords
This publication has 23 references indexed in Scilit:
- Cabergoline-Related Severe Restrictive Mitral RegurgitationNew England Journal of Medicine, 2005
- Diagnosis and Initial Management of Parkinson's DiseaseNew England Journal of Medicine, 2005
- Pergolide use in Parkinson disease is associated with cardiac valve regurgitationNeurology, 2004
- Severe multivalvular heart disease: A new complication of the ergot derivative dopamine agonistsMovement Disorders, 2004
- Treatment of Parkinson's disease with pergolide and relation to restrictive valvular heart diseaseThe Lancet, 2004
- Heart valvular disease in patients with Parkinson’s disease treated with high-dose pergolideNeurology, 2003
- The US Food and Drug Administration's Registry of Patients With Pergolide-Associated Valvular Heart DiseaseMayo Clinic Proceedings, 2003
- Restless Legs SyndromeNew England Journal of Medicine, 2003
- Valvular Heart Disease in Patients Taking PergolideMayo Clinic Proceedings, 2002
- Fibrotic Valvular Heart Disease Subsequent to Bromocriptine TreatmentCardiology in Review, 2002